Thermo Fisher Positioned As Biopharma's Partner Of Choice

William Blair initiated coverage on Thermo Fisher Scientific (TMO) with an Outperform rating and a $598 price target by 2026, representing 22% upside. Despite the stock's 27% decline since 2021, lagging the S&P 500, the firm cites TMO's strong balance sheet, impressive M&A track record, and recent Q2 2025 earnings beat as drivers for a significant turnaround. The outlook anticipates multiple expansion as industry headwinds resolve, positioning TMO as a top large-cap option for investors seeking recovery in the life science tools and pharma services sector.

Analysis

William Blair has initiated coverage on Thermo Fisher Scientific (TMO) with an Outperform rating, projecting a share price of $598 by the end of 2026, which represents a 22% upside from its recent price of $498.07. This optimistic outlook is framed against a period of significant underperformance, where TMO's stock has fallen 27% since the end of 2021, lagging the S&P 500's 30% gain. However, this decline aligns with broader sector weakness, as life science tools and pharma services peers fell 45% and 17% respectively over the same period. The analyst's thesis is anchored in the company's strong fundamentals, including a robust balance sheet and a successful M&A strategy that has significantly bolstered its biopharma services offerings, now accounting for approximately one-third of total company sales. This is supported by recent financial performance, with Q2 2025 adjusted EPS of $5.36 and sales of $10.86 billion both beating consensus estimates. The price target is predicated on the P/E multiple expanding from current lows to its 10-year average of approximately 22x as industry headwinds subside, positioning TMO as a prime large-cap candidate to capitalize on a recovery in the life sciences sector.

Key Decisions for Investors

• Investors with a constructive view on the life sciences sector should consider TMO as a core large-cap holding, given the analyst's Outperform rating and a 22% upside to the $598 price target.
• Monitor TMO's valuation multiple; the investment thesis relies on its P/E ratio reverting from current lows toward its 10-year average of 22.4x as a key driver for share price appreciation.
• Future M&A activity should be viewed as a potential catalyst, as the company's strategy leverages acquisitions in high-growth areas to enhance its market share and return on invested capital.
• The stock's performance is tied to a broader recovery in the pharma services and life science tools space, so investors should track sector-level funding and R&D trends as leading indicators.